Thompson Davis & Co’s TG Therapeutics TGTX Stock Holding History

Thompson Davis & Co’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,500	Closed	-$21K	–	742
2018 Q1	$21K	Buy	1,500 +250	+20%	+$3.19K	0.06%	285
2017 Q4	$10K	Sell	1,250 -1,782	-59%	-$15.6K	0.02%	417
2017 Q3	$36K	Hold	3,032	–	–	0.06%	315
2017 Q2	$30K	Sell	3,032 -10,216	-77%	-$114K	0.05%	335
2017 Q1	$154K	Buy	+13,248	New	+$95.1K	0.22%	97
2015 Q2	–	Sell	-3,500	Closed	-$54K	–	1252
2015 Q1	$54K	Sell	3,500 -750	-18%	-$11.4K	0.06%	282
2014 Q4	$67K	Sell	4,250 -750	-15%	-$9.77K	0.08%	233
2014 Q3	$53K	Buy	5,000 +4,750	+1,900%	+$44K	0.07%	261
2014 Q2	$2K	Sell	250 -250	-50%	-$1.6K	﹤0.01%	725
2014 Q1	$4K	Sell	500 -500	-50%	-$2.96K	0.01%	673
2013 Q4	$4K	Buy	+1,000	New	+$4.04K	0.01%	595

Other funds holding TGTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Thompson Davis & Co's TGTX Position: Q2 2018 in Review

Thompson Davis & Co sold out of TG Therapeutics (TGTX) in Q2 2018, closing a stake of 1,500 shares — an estimated $21K sold.

Thompson Davis & Co first reported a position in TGTX in Q4 2013 and held it in 11 quarters. The position peaked at $154K in Q1 2017. 132 funds tracked by Wall St. Rank hold TGTX as of Q2 2018.

Thompson Davis & Co reported no remaining TG Therapeutics position as of Q2 2018 after selling out during the quarter.
Thompson Davis & Co sold 1,500 TG Therapeutics shares in Q2 2018, an estimated $21K.
Thompson Davis & Co first reported a position in TG Therapeutics in Q4 2013 and held it in 11 quarters.
Thompson Davis & Co's TG Therapeutics position peaked at $154K in Q1 2017.
132 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2018.

Based on Thompson Davis & Co's 13F filing for Q2 2018, filed 3 Aug 2018.